Black Diamond Therapeutics (BDTX) risk factors, FY2024 10-K

Risks related to clinical development

1. 01Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates. We may find it difficult to enroll patients in our Phase 2 clinical trial for BDTX-1535 or future product candidates with the genetic mutations these product candidates are designed to target
2. 02We have limited experience as a company in conducting clinical trials
3. 03Our preclinical studies and clinical trials may fail to demonstrate adequately the safety, potency, purity and efficacy of any of our product candidates, which would prevent or delay development, regulatory approval and commercialization
4. 04We may not be able to file INDs or IND amendments to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed
5. 05We are conducting the clinical trial for our lead product candidate at clinical sites outside the United States, and the FDA and comparable foreign regulatory authorities may not accept such data from such clinical sites

Risks related to our approach

1. 06We are focused on the development of precision medicines for patients with genetically defined cancers, which is a rapidly evolving area of science, and the approach we have taken to discover, and are taking to develop drugs is novel and may never lead to marketable products
2. 07Our approach to the development of product candidates is unproven, and we may not be successful in our efforts to develop product candidates with commercial value
3. 08The market opportunities for our product candidates may be relatively small and limited to those patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate

Risks related to global events

1. 09Business, economic or geopolitical disruptions or global health concerns could seriously harm our development efforts and increase our costs and expenses
2. 10We or third parties upon whom we depend may be adversely affected by natural disasters, global health pandemics, armed conflicts, trade restrictions, or other business interruptions, and our business, financial condition and results of operations could be adversely affected

Risks related to sales, marketing and competition

1. 11We currently have no marketing and sales organization and have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved, we may not be able to generate product revenue
2. 12A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business
3. 13We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
4. 14Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community
5. 15If our product candidates are licensed but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue
6. 16We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do

Risks related to past financial condition

1. 17Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability
2. 18We have incurred significant losses since inception, and we expect to incur losses over the next several years and may not be able to achieve or sustain revenues or profitability in the future
3. 19We have not generated any revenue from our product candidates and may never be profitable

Risks related to future financial condition

1. 20We will need substantial additional funding. If we are unable to raise capital when needed, we would be compelled to delay, reduce or eliminate our product development programs or commercialization efforts

Risks related to government regulation

1. 21If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired
2. 22Our clinical trials may fail to demonstrate adequately the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization
3. 23We may seek orphan drug status for BDTX-1535 and some of our other future product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug status, including market exclusivity, which may cause our revenue, if any, to be reduced
4. 24A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval
5. 25A Fast Track designation by the FDA may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval
6. 26We may seek approval of our product candidates, where applicable, under the FDA’s accelerated approval pathway. This pathway may not lead to a faster development, regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval
7. 27If we are unable to successfully validate, develop and obtain regulatory approval for companion diagnostic tests for our drug candidates that are required or experience significant delays in doing so, we may not realize the full commercial potential of these drug candidates
8. 28Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions

Risks related to ongoing regulatory obligations

1. 29The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses
2. 30Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations
3. 31We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures
4. 32Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability
5. 33Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
6. 34If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business

Risks related to protecting our intellectual property

1. 35If we fail to comply with our obligations in any future agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our future licensors, we could lose license rights that are important to our business
2. 36If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
3. 37Because developing our product candidates may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights
4. 38Any issued patents we may own or in-license in the future covering our product candidates could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the USPTO
5. 39Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and patent protection could be reduced or eliminated for non-compliance with these requirements
6. 40We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world
7. 41If we do not obtain patent term extension and data exclusivity for any of our current or future product candidates we may develop, our business may be materially harmed
8. 42If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our marks of interest and our business may be adversely affected
9. 43Numerous factors may limit any potential competitive advantage provided by our intellectual property rights

Risks related to intellectual property litigation

1. 44Third-party claims of intellectual property infringement, misappropriation or other violations may be costly and time consuming and may prevent or delay our product discovery and development efforts
2. 45We may be involved in lawsuits to protect or enforce our intellectual property rights, including any patents we may own or in-license in the future, which could be expensive, time-consuming and unsuccessful
3. 46We may be subject to claims challenging the inventorship or ownership of any intellectual property, including any patents we may own or in-license in the future
4. 47We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information or alleged trade secrets of third parties or competitors or are in breach of non-competition or non-solicitation agreements with our competitors

Risks related to our reliance on third parties

1. 48We rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates
2. 49We may form or seek collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such collaborations, alliances or licensing arrangements
3. 50Our manufacturing process needs to comply with FDA regulations relating to the quality and reliability of such processes. Any failure to comply with relevant regulations could result in delays in or termination of our clinical programs and suspension or withdrawal of any regulatory approvals
4. 51If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages

Risks related to our employee matters

1. 52We are highly dependent on our key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy

Risks related to our business operations and growth

1. 53We may need to grow the size of our organization, and we may experience difficulties in managing this growth
2. 54Our internal computer systems, or those used by our third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of the development programs of our product candidates
3. 55If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates
4. 56The increasing use of social media platforms presents risks and challenges
5. 57We may fail to realize some or all of the anticipated benefits of the contribution of assets and license to Revelio Therapeutics, Inc

Risks related to tax

1. 58Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited

Risks related to investments in our securities

1. 59The price of our stock is volatile, and you could lose all or part of your investment
2. 60Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
3. 61We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock
4. 62Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant influence over matters subject to stockholder approval
5. 63We are an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors
6. 64We are incurring, and will continue to incur, significant increased expenses and administrative burdens as a public company, which could have an adverse effect on our business, financial condition and results of operations
7. 65Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall
8. 66Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price
9. 67If securities or industry analysts publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
10. 68Increased attention to, and evolving expectations for, environmental, social, and governance (ESG) initiatives could increase our costs, harm our reputation, or otherwise adversely impact our business

Risks related to our charter and bylaws

1. 69Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control, which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management

Risks related to internal control over financial reporting

1. 70If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed
2. 71Data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information
3. 72Changes to patent law in the United States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
4. 73Changes in tax law could adversely affect our business and financial condition
5. 74Conditions in the banking system and financial markets, including the failure of banks and financial institutions, could have an adverse effect on our operations and financial results
6. 75The U.S. Congress, the Trump administration, or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business

Risks related to cybersecurity

1. 76We may be unable to adequately protect our information systems from cyberattacks, security incidents, or compromises, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure